BETRF (BetterLife Pharma) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BETRF BetterLife Pharma Inc BETRF
24 GF Score
Price $0.16
! 2 Warning Signs
View Full Analysis

What is BetterLife Pharma Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of BetterLife Pharma is: No Data: Cannot be evaluated.

BetterLife Pharma  (OTCPK:BETRF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

BetterLife Pharma Risk Assessment Related Terms

BETRF vs VRTX, REGN, ALNY: Risk Assessment Comparison

For the Biotechnology subindustry, BetterLife Pharma's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BetterLife Pharma Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BetterLife Pharma's Risk Assessment distribution charts can be found below:

* The bar in red indicates where BetterLife Pharma's Risk Assessment falls into.


BETRF
24GF Score
BetterLife Pharma Inc BETRF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BetterLife Pharma Business Description

Other Exchanges NPAU:GermanyBETR:Canada
Address 1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6
BetterLife Pharma Inc is a biopharmaceutical company engaged in the development of patented pharmaceuticals. It is an emerging biotechnology company mainly focused on developing compounds for the treatment of mental disorders. It is also refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight viral infections. The Company operates in one industry segment, development and commercialization of patented pharmaceuticals within one geographical area.
24GF Score

Get the complete analysis for BETRF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price